Physics and Dosimetry: Inhomogeneity Correction in Lung SBRT
A 72-year-old woman with a 2.5 cm peripheral lung metastasis from breast cancer is being planned for stereotactic body radiotherapy (SBRT) using volumetric modulated arc therapy (VMAT). The planning CT shows the tumor abutting the chest wall but not the mediastinum. The treatment planning system (TPS) calculates dose using the anisotropic analytical algorithm (AAA) with and without inhomogeneity correction. The prescription is 48 Gy in 4 fractions to the 95% isodose line covering the PTV. The physicist notes a 12% difference in the mean PTV dose between the two calculations.
1. Which dose calculation should be used for clinical treatment, and why?
Read the worked answer
The dose calculation with inhomogeneity correction (AAA with correction) should be used. Lung tissue has a much lower density than water, and photon transport is altered: without correction, the TPS may overestimate dose in the lung and underestimate dose in the tumor due to lack of scatter and attenuation differences. For SBRT in the lung, accurate dose calculation is critical because of the high dose per fraction and steep dose gradients. The 12% difference in mean PTV dose is clinically significant. Guidelines (e.g., AAPM TG-101) recommend using algorithms that account for tissue inhomogeneities, such as AAA or Acuros XB, and validating them against Monte Carlo or measurement. Using the corrected calculation ensures that the prescribed dose is actually delivered to the target and avoids underdosing the tumor or overdosing critical structures.
2. What additional quality assurance steps would you perform for this SBRT plan?
Read the worked answer
For lung SBRT with VMAT, a comprehensive QA program is essential. Steps include: (1) independent dose calculation with a second algorithm (e.g., Monte Carlo) to verify the TPS; (2) measurement-based verification using a 2D or 3D detector array in a phantom with inhomogeneities (e.g., lung-equivalent material) to confirm dose distribution; (3) film dosimetry for high-resolution verification of steep gradients; (4) end-to-end testing with anthropomorphic phantom to verify targeting and dose delivery; (5) verification of tumor motion management if motion is present (4D CT, abdominal compression, or gating); (6) review of dose-volume constraints for organs at risk (spinal cord, heart, esophagus, brachial plexus) per TG-101; (7) chart rounds peer review; and (8) pre-treatment cone-beam CT for setup verification. The 12% difference between algorithms underscores the need for rigorous validation.